Arrowhead Research Corporation
ARWRNasdaqCIK 879407Healthcare / Drug Manufacturersfiscal year ends September65 quarters since 2010
Revenue, Q3 FY2026
$75M
+171.0% on Q3 FY2025
Net income
−$194M
−10.9% on Q3 FY2025
Free cash flow
−$181M
−15.4% on Q3 FY2025
Diluted EPS
$-1.36
−7.9% on Q3 FY2025
Revenue, TTM
$669M
trailing four quarters
Net margin, TTM
-47.8%
net income −$320M
Free cash flow, TTM
−$75M
−$59M less $16M capex
Cash and equivalents
—
long-term debt —, Jun 30, 2026
Shares, 12-month change
+2.2%
141M shares, Jun 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Latest quarter Q3 FY2026, filed August 4, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.
In Q3 FY2026, the quarter ended June 30, 2026, Arrowhead Research Corporation reported revenue of $75M, +171.0% on Q3 FY2025, and net loss of $194M (−10.9%). Operating margin was −226.0%. Free cash flow, operating cash flow less capital expenditures, was −$181M (−$177M less $4M). Diluted earnings per share were $-1.36.
Share price
Daily candlesticks from November 11, 2024 to November 9, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.
ARWR daily priceSplit-adjusted, US dollars; an earnings release
Nov 9, 2026O $52.49 · H $53.63 · L $46.45 · C $49.24 · −15.34% on the dayOver the range: +25.52%, Nov 10, 2025 to Nov 9, 2026
The last 16 quarters
Q4 FY2022 to Q3 FY2026, through the filing of August 4, 2026.
Net income losses drawn in red.
Operating cash flow less capital expenditures; negative quarters in red.
Positions at each quarter end, as filed; short-term investments are not included.
Income statement
Last eight quarters, newest first, through Q3 FY2026 filed August 4, 2026.
| Millions of dollars | Q3 FY2026ended Jun 30, 2026filed Aug 4, 2026 | Q2 FY2026ended Mar 31, 2026filed May 7, 2026 | Q1 FY2026ended Dec 31, 2025filed Feb 5, 2026 | Q4 FY2025ended Sep 30, 2025filed Nov 25, 2025 | Q3 FY2025ended Jun 30, 2025filed Aug 7, 2025 | Q2 FY2025ended Mar 31, 2025filed May 12, 2025 | Q1 FY2025ended Dec 31, 2024filed Feb 10, 2025 | Q4 FY2024ended Sep 30, 2024filed Nov 26, 2024 | YoYQ3 FY2026vs Q3 FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 75 | 74 | 264 | 256 | 28 | 543 | 3 | 0 | +171.0% |
| Cost of revenue | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Research and development | 198 | 173 | 177 | 175 | 162 | 133 | 137 | — | +22.1% |
| Selling, general and administrative | 47 | 42 | 46 | 38 | 31 | 28 | 27 | 26 | +52.3% |
| Operating income | (170) | (141) | 41 | 44 | (166) | 381 | (161) | (162) | −2.7% |
| Other income (expense) | (9) | 4 | (13) | (8) | (14) | (12) | (14) | (11) | +34.9% |
| Pretax income | (179) | (138) | 28 | 36 | (179) | 370 | (175) | (173) | +0.1% |
| Income tax | 0 | 0 | 0 | 20 | 0 | 2 | 0 | 1 | +102.5% |
| Net income | (194) | (133) | 31 | (24) | (175) | 370 | (173) | (171) | −10.9% |
| Diluted EPS ($) | (1.36) | (0.93) | 0.22 | — | (1.26) | 2.75 | (1.39) | — | −7.9% |
| Diluted shares (millions) | 143 | 142 | 141 | — | 139 | 134 | 125 | — | — |
Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.
Balance sheet
Last eight quarters, newest first, through Q3 FY2026 filed August 4, 2026.
| Millions of dollars | Q3 FY2026ended Jun 30, 2026filed Aug 4, 2026 | Q2 FY2026ended Mar 31, 2026filed May 7, 2026 | Q1 FY2026ended Dec 31, 2025filed Feb 5, 2026 | Q4 FY2025ended Sep 30, 2025filed Nov 25, 2025 | Q3 FY2025ended Jun 30, 2025filed Aug 7, 2025 | Q2 FY2025ended Mar 31, 2025filed May 12, 2025 | Q1 FY2025ended Dec 31, 2024filed Feb 10, 2025 | Q4 FY2024ended Sep 30, 2024filed Nov 26, 2024 | YoYQ3 FY2026vs Q3 FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | — | — | — | — | — | — | — | — |
| Short-term investments | 1,547 | 1,596 | 715 | 693 | 771 | 912 | 499 | 578 | +100.8% |
| Total current assets | 1,671 | 1,840 | 1,174 | 951 | 947 | 1,135 | 571 | 695 | +76.5% |
| Total assets | 2,112 | 2,268 | 1,604 | 1,385 | 1,381 | 1,573 | 1,014 | 1,140 | +53.0% |
| Total current liabilities | 283 | 295 | 347 | 195 | 195 | 221 | 94 | 103 | +45.7% |
| Long-term debt | — | — | — | — | — | — | — | — | — |
| Total liabilities | — | — | — | — | — | — | — | — | — |
| Stockholders’ equity | 466 | 614 | 568 | 466 | 522 | 683 | 53 | 185 | −10.9% |
| Shares outstanding (millions) | 141 | 141 | 140 | 136 | 138 | 138 | 126 | 124 | — |
Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.
Cash flow statement
Last eight quarters, newest first, through Q3 FY2026 filed August 4, 2026.
| Millions of dollars | Q3 FY2026ended Jun 30, 2026filed Aug 4, 2026 | Q2 FY2026ended Mar 31, 2026filed May 7, 2026 | Q1 FY2026ended Dec 31, 2025filed Feb 5, 2026 | Q4 FY2025ended Sep 30, 2025filed Nov 25, 2025 | Q3 FY2025ended Jun 30, 2025filed Aug 7, 2025 | Q2 FY2025ended Mar 31, 2025filed May 12, 2025 | Q1 FY2025ended Dec 31, 2024filed Feb 10, 2025 | Q4 FY2024ended Sep 30, 2024filed Nov 26, 2024 | YoYQ3 FY2026vs Q3 FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | (177) | 84 | 13 | 20 | (155) | 460 | (146) | (137) | −14.7% |
| Capital expenditures | 4 | 3 | 2 | 7 | 2 | 5 | 8 | 24 | +63.0% |
| Free cash flow (CFO − capex) | (181) | 82 | 11 | 13 | (157) | 455 | (154) | (162) | −15.4% |
| Depreciation and amortization | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | +6.9% |
| Share repurchases | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — |
10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.
Annual statements
Every fiscal year filed, newest first, through FY2025 filed November 25, 2025.
Income statement
| Millions of dollars | FY2025ended Sep 30, 2025filed Nov 25, 2025 | FY2024ended Sep 30, 2024filed Nov 26, 2024 | FY2023ended Sep 30, 2023filed Nov 29, 2023 | FY2022ended Sep 30, 2022filed Nov 28, 2022 | FY2021ended Sep 30, 2021filed Nov 22, 2021 | FY2020ended Sep 30, 2020filed Nov 23, 2020 | FY2019ended Sep 30, 2019filed Nov 25, 2019 | FY2018ended Sep 30, 2018filed Dec 11, 2018 | FY2017ended Sep 30, 2017filed Dec 12, 2017 | FY2016ended Sep 30, 2016filed Dec 14, 2016 | FY2015ended Sep 30, 2015filed Dec 14, 2015 | FY2014ended Sep 30, 2014filed Nov 25, 2014 | FY2013ended Sep 30, 2013filed Dec 18, 2013 | FY2012ended Sep 30, 2012filed Dec 28, 2012 | FY2011ended Sep 30, 2011filed Dec 20, 2011 | FY2010ended Sep 30, 2010filed Aug 8, 2011 | FY2009ended Sep 30, 2009filed Aug 8, 2011 | FY2008ended Sep 30, 2008filed Aug 8, 2011 | FY2007ended Sep 30, 2007filed Aug 8, 2011 | FY2006ended Sep 30, 2006filed Aug 8, 2011 | FY2005ended Sep 30, 2005filed Aug 8, 2011 | FY2004ended Sep 30, 2004filed Aug 8, 2011 | FY2003ended Sep 30, 2003filed Aug 8, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 829 | 4 | 241 | 243 | 138 | 88 | 169 | 16 | 31 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research and development | 607 | 506 | 353 | — | — | — | — | — | — | — | 47 | 23 | 9 | 5 | 3 | 1 | — | — | — | — | — | — | — |
| Selling, general and administrative | 124 | 99 | 93 | 124 | 81 | 52 | 27 | 19 | 17 | 24 | 8 | 6 | 3 | 6 | 4 | 2 | — | — | — | — | — | — | — |
| Operating income | 98 | (601) | (205) | (179) | (149) | (93) | 61 | (56) | (37) | (82) | (96) | (53) | (25) | (21) | (10) | (6) | — | — | — | — | — | — | — |
| Other income (expense) | (47) | (11) | (1) | 6 | 8 | 9 | 7 | 1 | 3 | 0 | 4 | (5) | (7) | (1) | 1 | 2 | — | — | — | — | — | — | — |
| Pretax income | 52 | (612) | (206) | (173) | (141) | (85) | 68 | (54) | (34) | (82) | (92) | (59) | (32) | (22) | (9) | (4) | — | — | — | — | — | — | — |
| Income tax | 21 | (3) | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — |
| Net income | (2) | (599) | (205) | (176) | (141) | (85) | 68 | (54) | (34) | (82) | (92) | (59) | (31) | (21) | (3) | (6) | (19) | (27) | (31) | (20) | (7) | (1) | 0 |
| Diluted EPS ($) | (0.01) | (5.00) | (1.92) | (1.67) | (1.36) | (0.84) | 0.69 | (0.65) | (0.47) | — | — | — | — | — | (0.40) | (0.90) | — | — | — | — | — | — | — |
| Diluted shares (millions) | 134 | 120 | 107 | 105 | 104 | 101 | 99 | 84 | 74 | — | — | — | — | — | 7,830* | 6,434* | — | — | — | — | — | — | — |
Balance sheet
| Millions of dollars | FY2025ended Sep 30, 2025filed Nov 25, 2025 | FY2024ended Sep 30, 2024filed Nov 26, 2024 | FY2023ended Sep 30, 2023filed Nov 29, 2023 | FY2022ended Sep 30, 2022filed Nov 28, 2022 | FY2021ended Sep 30, 2021filed Nov 22, 2021 | FY2020ended Sep 30, 2020filed Nov 23, 2020 | FY2019ended Sep 30, 2019filed Nov 25, 2019 | FY2018ended Sep 30, 2018filed Dec 11, 2018 | FY2017ended Sep 30, 2017filed Dec 12, 2017 | FY2016ended Sep 30, 2016filed Dec 14, 2016 | FY2015ended Sep 30, 2015filed Dec 14, 2015 | FY2014ended Sep 30, 2014filed Nov 25, 2014 | FY2013ended Sep 30, 2013filed Dec 18, 2013 | FY2012ended Sep 30, 2012filed Dec 28, 2012 | FY2011ended Sep 30, 2011filed Dec 20, 2011 | FY2010ended Sep 30, 2010filed Aug 8, 2011 | FY2009ended Sep 30, 2009filed Aug 8, 2011 | FY2008ended Sep 30, 2008filed Aug 8, 2011 | FY2007ended Sep 30, 2007filed Aug 8, 2011 | FY2006ended Sep 30, 2006filed Aug 8, 2011 | FY2005ended Sep 30, 2005filed Aug 8, 2011 | FY2004ended Sep 30, 2004filed Aug 8, 2011 | FY2003ended Sep 30, 2003filed Aug 8, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | — | — | — | 184 | 144 | 222 | 30 | 25 | 85 | 81 | 133 | 19 | 3 | 8 | 7 | 2 | — | — | — | — | — | — |
| Short-term investments | 693 | 578 | 293 | 0 | 127 | 85 | — | — | — | — | — | 22 | 9 | 0 | 1 | — | — | — | — | — | — | — | — |
| Total current assets | 951 | 695 | 416 | 405 | 385 | 322 | 265 | 79 | 68 | 91 | 103 | 155 | 29 | 7 | 10 | 8 | — | — | — | — | — | — | — |
| Total assets | 1,385 | 1,140 | 766 | 692 | 710 | 523 | 350 | 112 | 104 | 128 | 132 | 183 | 37 | 17 | 16 | 12 | — | — | — | — | — | — | — |
| Total current liabilities | 195 | 103 | 105 | 139 | 147 | 41 | 97 | 12 | 19 | 26 | 16 | 12 | 9 | 5 | 3 | 4 | — | — | — | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total liabilities | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stockholders’ equity | 466 | 185 | 271 | 399 | 409 | 462 | 245 | 96 | 81 | 96 | 110 | 167 | 27 | 10 | 13 | 9 | — | — | — | — | — | — | — |
| Shares outstanding (millions) | 136 | 124 | 107 | 106 | 105 | 103 | 96 | 92 | 75 | 74 | 60 | 55 | 39 | 16 | 11 | — | — | — | — | — | — | — | — |
Cash flow statement
| Millions of dollars | FY2025ended Sep 30, 2025filed Nov 25, 2025 | FY2024ended Sep 30, 2024filed Nov 26, 2024 | FY2023ended Sep 30, 2023filed Nov 29, 2023 | FY2022ended Sep 30, 2022filed Nov 28, 2022 | FY2021ended Sep 30, 2021filed Nov 22, 2021 | FY2020ended Sep 30, 2020filed Nov 23, 2020 | FY2019ended Sep 30, 2019filed Nov 25, 2019 | FY2018ended Sep 30, 2018filed Dec 11, 2018 | FY2017ended Sep 30, 2017filed Dec 12, 2017 | FY2016ended Sep 30, 2016filed Dec 14, 2016 | FY2015ended Sep 30, 2015filed Dec 14, 2015 | FY2014ended Sep 30, 2014filed Nov 25, 2014 | FY2013ended Sep 30, 2013filed Dec 18, 2013 | FY2012ended Sep 30, 2012filed Dec 28, 2012 | FY2011ended Sep 30, 2011filed Dec 20, 2011 | FY2010ended Sep 30, 2010filed Aug 8, 2011 | FY2009ended Sep 30, 2009filed Aug 8, 2011 | FY2008ended Sep 30, 2008filed Aug 8, 2011 | FY2007ended Sep 30, 2007filed Aug 8, 2011 | FY2006ended Sep 30, 2006filed Aug 8, 2011 | FY2005ended Sep 30, 2005filed Aug 8, 2011 | FY2004ended Sep 30, 2004filed Aug 8, 2011 | FY2003ended Sep 30, 2003filed Aug 8, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 180 | (463) | (154) | (136) | 171 | (96) | 173 | (47) | (24) | (64) | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Capital expenditures | 23 | 141 | 177 | 53 | 24 | 12 | 12 | 1 | 8 | 4 | 2 | 2 | 0 | 0 | 0 | — | — | — | — | — | — | — | — |
| Free cash flow (CFO − capex) | 157 | (604) | (331) | (189) | 148 | (108) | 161 | (49) | (32) | (68) | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation and amortization | 22 | 17 | 11 | 9 | 7 | 4 | 3 | 3 | 3 | 3 | 2 | 1 | 2 | 2 | 0 | 0 | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Insider activity
Form 4 filings by officers, directors and 10% owners, November 9, 2024 to November 9, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.
Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$1M
2 sales by 2 insiders; officers and directors $1M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$37M
64 sales by 10 insiders; officers and directors $37M
The last 25 transactions
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Olukotun Adeoye Y | Director | open-market sale | 2,000 | $86.96 | $174K | 31,600 | Aug 20, 2026 |
| Aug 18, 2026 | Perry Michael S | Director | open-market sale | 11,600 | $87.30 | $1M | 111,459 | Aug 20, 2026 |
| Jun 15, 2026 | Cohen Matthew Gregory | Director | award | 11,882 | $0.00 | — | 11,882 | Jun 17, 2026 |
| May 12, 2026 | Lu Hongbo | Director | open-market sale10b5-1 | 2,970 | $76.88 | $228K | 52,012 | May 14, 2026 |
| Apr 23, 2026 | Hamilton James C | Chief Medical Officer | open-market sale10b5-1 | 10,000 | $75.00 | $750K | 226,958 | Apr 24, 2026 |
| Apr 22, 2026 | Apel Daniel Joseph | Chief Financial Officer | open-market sale10b5-1 | 3,208 | $70.11 | $225K | 172,792 | Apr 24, 2026 |
| Apr 22, 2026 | Apel Daniel Joseph | Chief Financial Officer | open-market sale10b5-1 | 1,157 | $70.45 | $82K | 171,635 | Apr 24, 2026 |
| Apr 22, 2026 | Apel Daniel Joseph | Chief Financial Officer | open-market sale10b5-1 | 8,730 | $71.92 | $628K | 162,905 | Apr 24, 2026 |
| Mar 5, 2026 | Hamilton James C | Chief Medical Officer | open-market sale10b5-1 | 10,000 | $64.19 | $642K | 236,958 | Mar 9, 2026 |
| Jan 6, 2026 | Hamilton James C | Chief Medical Officer | award | 75,000 | $0.00 | — | 246,958 | Jan 8, 2026 |
| Jan 6, 2026 | Apel Daniel Joseph | Chief Financial Officer | award | 75,000 | $0.00 | — | 176,200 | Jan 8, 2026 |
| Jan 6, 2026 | O'Brien Patrick | COO | gift | 540 | $0.00 | — | 473,288 | Jan 8, 2026 |
| Jan 6, 2026 | O'Brien Patrick | COO | award | 75,000 | $0.00 | — | 547,408 | Jan 8, 2026 |
| Jan 6, 2026 | O'Brien Patrick | COO | gift | 440 | $0.00 | — | 472,408 | Jan 8, 2026 |
| Jan 6, 2026 | O'Brien Patrick | COO | gift | 540 | $0.00 | — | 473,828 | Jan 8, 2026 |
| Jan 6, 2026 | O'Brien Patrick | COO | gift | 540 | $0.00 | — | 474,368 | Jan 8, 2026 |
| Jan 6, 2026 | O'Brien Patrick | COO | gift | 440 | $0.00 | — | 472,848 | Jan 8, 2026 |
| Jan 5, 2026 | O'Brien Patrick | COO | open-market sale10b5-1 | 46 | $68.00 | $3K | 474,908 | Jan 5, 2026 |
| Jan 5, 2026 | O'Brien Patrick | COO | open-market sale10b5-1 | 4,368 | $61.20 | $267K | 520,033 | Jan 5, 2026 |
| Jan 5, 2026 | O'Brien Patrick | COO | open-market sale10b5-1 | 6,164 | $62.23 | $384K | 513,869 | Jan 5, 2026 |
| Jan 5, 2026 | O'Brien Patrick | COO | open-market sale10b5-1 | 13,451 | $62.96 | $847K | 500,418 | Jan 5, 2026 |
| Jan 5, 2026 | O'Brien Patrick | COO | open-market sale10b5-1 | 11,842 | $63.84 | $756K | 488,576 | Jan 5, 2026 |
| Jan 5, 2026 | O'Brien Patrick | COO | open-market sale10b5-1 | 2,700 | $64.44 | $174K | 485,876 | Jan 5, 2026 |
| Jan 5, 2026 | O'Brien Patrick | COO | open-market sale10b5-1 | 900 | $66.01 | $59K | 484,976 | Jan 5, 2026 |
| Jan 5, 2026 | O'Brien Patrick | COO | open-market sale10b5-1 | 313 | $68.00 | $21K | 484,663 | Jan 5, 2026 |
Full insider history for Arrowhead Research Corporation, or insider activity across all companies. A record of filings, not a recommendation.
Sources
Fiscal year ends in month 9; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.
- Filer
- ARROWHEAD PHARMACEUTICALS, INC., CIK 879407 on EDGAR
- Extract generated
- November 8, 2026
- Withheld
- none
- Repaired
- 1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: other income FY2017
XBRL concepts behind each line
Income statement
Revenue:
RevenueFromContractWithCustomerExcludingAssessedTax, RevenuesCost of revenue: not filed
Gross profit: not filed
Research and development:
ResearchAndDevelopmentExpenseSelling, general and administrative:
GeneralAndAdministrativeExpense, SellingGeneralAndAdministrativeExpenseOperating income:
OperatingIncomeLossOther income (expense):
NonoperatingIncomeExpensePretax income:
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax:
IncomeTaxExpenseBenefitNet income:
NetIncomeLossDiluted EPS ($):
EarningsPerShareDilutedDiluted shares (millions):
WeightedAverageNumberOfDilutedSharesOutstandingBalance sheet
Cash and equivalents:
CashAndCashEquivalentsAtCarryingValueShort-term investments:
AvailableForSaleSecuritiesDebtSecuritiesCurrent, MarketableSecuritiesCurrent, ShortTermInvestmentsTotal current assets:
AssetsCurrentTotal assets:
AssetsTotal current liabilities:
LiabilitiesCurrentLong-term debt: not filed
Total liabilities: not filed
Stockholders’ equity:
StockholdersEquityShares outstanding (millions):
dei:EntityCommonStockSharesOutstandingCash flow statement
Operating cash flow:
NetCashProvidedByUsedInOperatingActivitiesCapital expenditures:
PaymentsToAcquirePropertyPlantAndEquipmentFree cash flow (CFO − capex): not filed
Depreciation and amortization:
DepreciationAndAmortization, DepreciationDepletionAndAmortizationShare repurchases: not filed
Dividends paid: not filed
The data
The statements on this page as files, generated November 8, 2026.
- JSON file
/data/financials/ARWR.json